Literature DB >> 9038690

Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass.

H Schunkert1, H W Hense, M Muscholl, A Luchner, S Kürzinger, A H Danser, G A Riegger.   

Abstract

OBJECTIVE: Cardiac growth may be modulated in part by the trophic effects of neurohormones. The aim of the present study was to investigate the relation between the basal activity of the renin-angiotensin-aldosterone system and left ventricular mass.
DESIGN: A population based sample of 615 middle-age subjects was studied by standardised echocardiography; anthropometric measurements; and biochemical quantification of renin, pro-renin, angiotensinogen, angiotensin converting enzyme (ACE), and aldosterone.
RESULTS: Echocardiographic left ventricular mass index correlated significantly with arterial blood pressure, age, and body mass index. In addition, in men ACE activity was significantly related to left ventricular mass index in univariate (P = 0.0007) and multivariate analyses (P = 0.008). Men with left ventricular hypertrophy presented with significantly higher serum ACE concentrations than those with normal left ventricular mass index (P = 0.002). In both men and women serum aldosterone was strongly related to septal and posterior wall thickness. Furthermore, in women serum aldosterone was positively and independently associated with left ventricular mass index (P = 0.0001). This effect was most prominent in hypertensive women. Finally, women with left ventricular hypertrophy presented with significantly higher serum aldosterone (P = 0.01). No significant associations with left ventricular mass index were observed for angiotensinogen, renin, or pro-renin.
CONCLUSIONS: The data suggest that the variability of serum ACE or aldosterone, as occurred in this large population based sample, may contribute to the modulation of left ventricular mass.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038690      PMCID: PMC484630          DOI: 10.1136/hrt.77.1.24

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  57 in total

1.  Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring.

Authors:  D Rizzoni; M L Muiesan; G Montani; R Zulli; S Calebich; E Agabiti-Rosei
Journal:  Am J Hypertens       Date:  1992-03       Impact factor: 2.689

2.  Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.

Authors:  H Schunkert; V J Dzau; S S Tang; A T Hirsch; C S Apstein; B H Lorell
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

3.  Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure.

Authors:  H Schunkert; J R Ingelfinger; A T Hirsch; S S Tang; S E Litwin; C E Talsness; V J Dzau
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

4.  Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.

Authors:  A Ganau; R B Devereux; M J Roman; G de Simone; T G Pickering; P S Saba; P Vargiu; I Simongini; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1992-06       Impact factor: 24.094

5.  Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction.

Authors:  F Cambien; O Costerousse; L Tiret; O Poirier; L Lecerf; M F Gonzales; A Evans; D Arveiler; J P Cambou; G Luc
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

6.  Molecular basis of human hypertension: role of angiotensinogen.

Authors:  X Jeunemaitre; F Soubrier; Y V Kotelevtsev; R P Lifton; C S Williams; A Charru; S C Hunt; P N Hopkins; R R Williams; J M Lalouel
Journal:  Cell       Date:  1992-10-02       Impact factor: 41.582

7.  Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody.

Authors:  F H Derkx; J Deinum; M Lipovski; M Verhaar; W Fischli; M A Schalekamp
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

Review 8.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

9.  The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study.

Authors:  M S Lauer; K M Anderson; W B Kannel; D Levy
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

10.  Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels.

Authors:  L Tiret; B Rigat; S Visvikis; C Breda; P Corvol; F Cambien; F Soubrier
Journal:  Am J Hum Genet       Date:  1992-07       Impact factor: 11.025

View more
  16 in total

1.  Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.

Authors:  Giuseppe Mulè; Emilio Nardi; Laura Guarino; Valentina Cacciatore; Giulio Geraci; Ilenia Calcaterra; Bruno Oddo; Francesco Vaccaro; Santina Cottone
Journal:  Hypertens Res       Date:  2015-01-08       Impact factor: 3.872

2.  Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.

Authors:  Miranda Merrill; Nancy K Sweitzer; JoAnn Lindenfeld; David P Kao
Journal:  JACC Heart Fail       Date:  2019-03       Impact factor: 12.035

3.  Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy.

Authors:  Wolfgang Lieb; Jochen Graf; Anika Götz; Inke R König; Björn Mayer; Marcus Fischer; Jan Stritzke; Christian Hengstenberg; Stephan R Holmer; Angela Döring; Hannelore Löwel; Heribert Schunkert; Jeanette Erdmann
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

Review 4.  Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.

Authors:  Adam Whaley-Connell; Megan S Johnson; James R Sowers
Journal:  Prog Cardiovasc Dis       Date:  2010 Mar-Apr       Impact factor: 8.194

5.  Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction.

Authors:  Vinod Jorapur; Gervasio A Lamas; Zygmunt P Sadowski; Harmony R Reynolds; Antonio C Carvalho; Christopher E Buller; James M Rankin; Jean Renkin; Philippe Gabriel Steg; Harvey D White; Carlos Vozzi; Eduardo Balcells; Michael Ragosta; C Edwin Martin; Vankeepuram S Srinivas; William W Wharton Iii; Staci Abramsky; Ana C Mon; Shari S Kronsberg; Judith S Hochman
Journal:  World J Cardiol       Date:  2010-01-26

Review 6.  Rationale for the use of aldosterone antagonists in congestive heart failure.

Authors:  Ricardo Rocha; Gordon H Williams
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension.

Authors:  Baojian Xue; Daniel Badaue-Passos; Fang Guo; Celso E Gomez-Sanchez; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-06       Impact factor: 4.733

Review 8.  Aldosterone receptor antagonists for hypertension: what do they offer?

Authors:  Danny Liew; Henry Krum
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics.

Authors:  S R Holmer; H W Hense; A H Danser; B Mayer; G A Riegger; H Schunkert
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

10.  Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.

Authors:  Rosemeire M Kanashiro-Takeuchi; Bettina Heidecker; Guillaume Lamirault; Jennifer W Dharamsi; Joshua M Hare
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.